Brief: Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
06/06/2025 12:14
June 6 (Reuters) - Arvinas Inc ARVN.O: ARVINAS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO U.S. FDA FOR VEPDEGESTRANT FOR PATIENTS WITH ESR1-MUTATED ER+/HER2- ADVANCED OR METASTATIC BREAST CANCER Source text: ID:nGNX8cRv83 Further company coverage: ARVN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arvinas
See all newsBrief: Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Arvinas Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Arvinas - Pfizer, And Rigel Receive Hart-Scott-Rodino Clearance For License Agreement On June 11, 2026
Brief: Arvinas - Announces Re-Prioritization Of Portfolio Following Strategic Review - SEC Filing
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology